Literature DB >> 26243362

Fracture prediction from repeat BMD measurements in clinical practice.

W D Leslie1,2, S L Brennan-Olsen3,4, S N Morin5, L M Lix6.   

Abstract

UNLABELLED: We investigated whether repeat BMD measurements in clinical populations are useful for fracture risk assessment. We report that repeat BMD measurements are a robust predictor of fracture in clinical populations; this is not affected by preceding BMD change or recent osteoporosis therapy.
INTRODUCTION: In clinical practice, many patients selectively undergo repeat bone mineral density (BMD) measurements. We investigated whether repeat BMD measurements in clinical populations are useful for fracture risk assessment and whether this is affected by preceding change in BMD or recent osteoporosis therapy.
METHODS: We identified women and men aged ≥ 50 years who had a BMD measurement during 1990-2009 from a large clinical BMD database for Manitoba, Canada (n = 50,215). Patient subgroups aged ≥ 50 years at baseline with repeat BMD measures were identified. Data were linked to an administrative data repository, from which osteoporosis therapy, fracture outcomes, and covariates were extracted. Using Cox proportional hazards models, we assessed covariate-adjusted risk for major osteoporotic fracture (MOF) and hip fracture according to BMD (total hip, lumbar spine, femoral neck) at different time points.
RESULTS: Prevalence of osteoporosis therapy increased from 18 % at baseline to 55 % by the fourth measurement. Total hip BMD was predictive of MOF at each time point. In the patient subgroup with two repeat BMD measurements (n = 13,481), MOF prediction with the first and second measurements was similar: adjusted-hazard ratio (HR) per SD 1.45 (95 % CI 1.34-1.56) vs. 1.64 (95 % CI 1.48-1.81), respectively. No differences were seen when the second measurement results were stratified by preceding change in BMD or osteoporosis therapy (both p-interactions >0.2). Similar results were seen for hip fracture prediction and when spine and femoral neck BMD were analyzed.
CONCLUSION: Repeat BMD measurements are a robust predictor of fracture in clinical populations; this is not affected by preceding BMD change or recent osteoporosis therapy.

Entities:  

Keywords:  Bone mineral density; Densitometry; Fracture prediction; Osteoporosis treatment

Mesh:

Substances:

Year:  2015        PMID: 26243362     DOI: 10.1007/s00198-015-3259-y

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  34 in total

1.  Revisiting the Manitoba Centre for Health Policy and Evaluation and its population-based health information system.

Authors:  N P Roos; E Shapiro
Journal:  Med Care       Date:  1999-06       Impact factor: 2.983

2.  Bone density screening intervals for osteoporosis: one size does not fit all.

Authors:  Elaine W Yu; Joel S Finkelstein
Journal:  JAMA       Date:  2012-06-27       Impact factor: 56.272

3.  Rate of bone density change does not enhance fracture prediction in routine clinical practice.

Authors:  William D Leslie; Suzanne N Morin; Lisa M Lix
Journal:  J Clin Endocrinol Metab       Date:  2012-01-25       Impact factor: 5.958

Review 4.  FRAX and its applications to clinical practice.

Authors:  John A Kanis; Anders Oden; Helena Johansson; Fredrik Borgström; Oskar Ström; Eugene McCloskey
Journal:  Bone       Date:  2009-02-03       Impact factor: 4.398

5.  Validation of an electronic, population-based prescription database.

Authors:  A L Kozyrskyj; C A Mustard
Journal:  Ann Pharmacother       Date:  1998-11       Impact factor: 3.154

6.  Does osteoporosis therapy invalidate FRAX for fracture prediction?

Authors:  William D Leslie; Lisa M Lix; Helena Johansson; Anders Oden; Eugene McCloskey; John A Kanis
Journal:  J Bone Miner Res       Date:  2012-06       Impact factor: 6.741

7.  Fracture prediction and calibration of a Canadian FRAX® tool: a population-based report from CaMos.

Authors:  L-A Fraser; L Langsetmo; C Berger; G Ioannidis; D Goltzman; J D Adachi; A Papaioannou; R Josse; C S Kovacs; W P Olszynski; T Towheed; D A Hanley; S M Kaiser; J Prior; S Jamal; N Kreiger; J P Brown; H Johansson; A Oden; E McCloskey; J A Kanis; W D Leslie
Journal:  Osteoporos Int       Date:  2010-12-16       Impact factor: 4.507

8.  Femoral neck bone loss predicts fracture risk independent of baseline BMD.

Authors:  Tuan V Nguyen; Jacqueline R Center; John A Eisman
Journal:  J Bone Miner Res       Date:  2005-02-21       Impact factor: 6.741

9.  Repeat bone mineral density screening and prediction of hip and major osteoporotic fracture.

Authors:  Sarah D Berry; Elizabeth J Samelson; Michael J Pencina; Robert R McLean; L Adrienne Cupples; Kerry E Broe; Douglas P Kiel
Journal:  JAMA       Date:  2013-09-25       Impact factor: 56.272

10.  Can change in FRAX score be used to "treat to target"? A population‐based cohort study.

Authors:  William D Leslie; Sumit R Majumdar; Lisa M Lix; Suzanne N Morin; Helena Johansson; Anders Odén; Eugene V McCloskey; John A Kanis
Journal:  J Bone Miner Res       Date:  2014       Impact factor: 6.741

View more
  3 in total

1.  Association between subclinical thyroid dysfunction and change in bone mineral density in prospective cohorts.

Authors:  D Segna; D C Bauer; M Feller; C Schneider; H A Fink; C E Aubert; T-H Collet; B R da Costa; K Fischer; R P Peeters; A R Cappola; M R Blum; H A van Dorland; J Robbins; K Naylor; R Eastell; A G Uitterlinden; F Rivadeneira Ramirez; A Gogakos; J Gussekloo; G R Williams; A Schwartz; J A Cauley; D A Aujesky; H A Bischoff-Ferrari; N Rodondi
Journal:  J Intern Med       Date:  2017-10-16       Impact factor: 8.989

2.  Accelerated Bone Loss in Older Men: Effects on Bone Microarchitecture and Strength.

Authors:  Jane A Cauley; Andrew J Burghardt; Stephanie L Harrison; Peggy M Cawthon; Ann V Schwartz; Elizabeth Barrett Connor; Kristine E Ensrud; Lisa Langsetmo; Sharmila Majumdar; Eric Orwoll
Journal:  J Bone Miner Res       Date:  2018-06-12       Impact factor: 6.741

Review 3.  Update on the Role of Neuropeptide Y and Other Related Factors in Breast Cancer and Osteoporosis.

Authors:  Shu-Ting Lin; Yi-Zhong Li; Xiao-Qi Sun; Qian-Qian Chen; Shun-Fa Huang; Shu Lin; Si-Qing Cai
Journal:  Front Endocrinol (Lausanne)       Date:  2021-08-06       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.